Zusduri™ (mitomycin) – New drug approval
June 12, 2025 - The FDA announced the approval of UroGen’s Zusduri (mitomycin), for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Download PDF
